Ceftolozane
- Generic Name
- Ceftolozane
- Brand Names
- Zerbaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N12O8S2
- CAS Number
- 689293-68-3
- Unique Ingredient Identifier
- 37A4IES95Q
- Background
Ceftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. It was approved by the FDA in 2014 for use in combination with Tazobactam for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections. The manufacturer of this drug is Cubist Pharmaceuticals. Most recently, in June 2019, ceftolozane-tazobactam was approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Hospital-acquired pneumonia and ventilator-associated pneumonia are major causes of morbidity and mortality in hospitalized patients and the use of ceftolozane-tazobactam offers effective activity against various organisms causing these infections, such as Pseudomonas aeruginosa.
- Indication
Ceftolozane is used in combination with tazobactam for the treatment of infections caused by designated susceptible microorganisms in adult and pediatric patients:
- Associated Conditions
- Nosocomial Pneumonia, Ventilator Associated Bacterial Pneumonia (VABP), Complicated Pyelonephritis, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated intra-abdominal bacterial infections
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.